|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...5556575859606162636465...6768» |
- | Biostate (factor VIII/von Willebrand factor) / CSL Behring
Enrollment open: Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (clinicaltrials.gov) - Jul 23, 2012
P3, N=20, Recruiting, Sponsor: CSL Behring
Not yet recruiting --> Recruiting
- Feiba (anti-inhibitor coagulant complex) / Takeda
Trial completion, Combination therapy: Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII (clinicaltrials.gov) - Jul 20, 2012
P4, N=5, Completed, Sponsor: Sheba Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | albumin-bound paclitaxel / Generic mfg.
New P2 trial: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 18, 2012
P2, N=30, Recruiting, Sponsor: Mayo Clinic
- | Ninlaro (ixazomib) / Takeda
New P1 trial: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 18, 2012
P1, N=24, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- ||| Ojjaara (momelotinib) / GSK
Enrollment closed, IO biomarker: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Jul 17, 2012
P1/2, N=61, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Enrollment closed: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Genetic Disease Investigators
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: EMMA-1 (Erbitux for Multiple Myeloma) (clinicaltrials.gov) - Jul 11, 2012
P2, N=13, Terminated, Sponsor: Prof. Dr. Andreas Engert
Recruiting --> Active, not recruiting Recruiting --> Terminated; Lack of recruitable patients
- BMS-833923 / BMS
Enrollment change, Combination therapy: Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jul 11, 2012
P1, N=27, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Terminated; Lack of recruitable patients N=66 --> 27
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: EMMA-1 (Erbitux for Multiple Myeloma) (clinicaltrials.gov) - Jul 11, 2012
P2, N=13, Terminated, Sponsor: Prof. Dr. Andreas Engert
N=66 --> 27 N=33 --> 13
- | BMS-833923 / BMS
Trial completion, Combination therapy: Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jul 11, 2012
P1, N=27, Completed, Sponsor: Bristol-Myers Squibb
N=33 --> 13 Recruiting --> Completed
- | samalizumab (ALXN 6000) / The Leukemia & Lymphoma Society, AstraZeneca
Enrollment change: Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (clinicaltrials.gov) - Jul 10, 2012
P1/2, N=26, Completed, Sponsor: Alexion Pharmaceuticals
Recruiting --> Completed N=57 --> 26
- bortezomib / Generic mfg., melphalan / Generic mfg.
Enrollment change: Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2012
P1, N=15, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=57 --> 26 N=24 --> 15
- bortezomib / Generic mfg., melphalan / Generic mfg.
Trial completion: Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2012
P1, N=15, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=24 --> 15 Active, not recruiting --> Completed
- Mozobil (plerixafor) / Sanofi
Enrollment change: Long-Term Follow Up Study for AMD3100 Patients (clinicaltrials.gov) - Jul 9, 2012
P=N/A, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=300 --> 7
- Mozobil (plerixafor) / Sanofi
Trial completion: Long-Term Follow Up Study for AMD3100 Patients (clinicaltrials.gov) - Jul 9, 2012
P=N/A, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
N=300 --> 7 Active, not recruiting --> Completed
- | Rebinyn (nonacog beta pegol) / Novo Nordisk
Enrollment change: Paradigm-2: Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (clinicaltrials.gov) - Jul 4, 2012
P3, N=74, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed N=53 --> 74
- Trial withdrawal: Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Jul 4, 2012
P=N/A, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
N=53 --> 74 Not yet recruiting --> Withdrawn
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
New P1 trial: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Jul 4, 2012
P1, N=22, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- ||| Edsivo (celiprolol) / Acer Therap
Enrollment change: Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type (clinicaltrials.gov) - Jul 3, 2012
P4, N=54, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Withdrawn N=100 --> 54
- everolimus / Generic mfg.
Enrollment change: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jul 2, 2012
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=100 --> 54 N=60 --> 33
- | perifosine (D21266) / AEterna Zentaris
Trial completion, Combination therapy: Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma (clinicaltrials.gov) - Jul 2, 2012
P1, N=32, Completed, Sponsor: AEterna Zentaris
N=60 --> 33 Active, not recruiting --> Completed
- ||| Xyntha (moroctocog alfa) / Pfizer
Enrollment open, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Jul 1, 2012
P=N/A, N=180, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Suspended --> Recruiting
- | Empliciti (elotuzumab) / AbbVie, BMS
New P2 trial, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 28, 2012
P2, N=40, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open, Monotherapy: XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease (clinicaltrials.gov) - Jun 27, 2012
P1, N=22, Recruiting, Sponsor: Massachusetts General Hospital
Suspended --> Recruiting Not yet recruiting --> Recruiting
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2012
P2, N=146, Completed, Sponsor: Wuerzburg University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial withdrawal: Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma (clinicaltrials.gov) - Jun 25, 2012
P3, N=0, Withdrawn, Sponsor: Novo Nordisk
Recruiting --> Completed Completed --> Withdrawn
- Trial withdrawal: Study Evaluating Inhibitor Specificity in Hemophilia A (clinicaltrials.gov) - Jun 25, 2012
P4, N=0, Withdrawn, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Completed --> Withdrawn Terminated --> Withdrawn
- Enrollment change: Study Evaluating Inhibitor Specificity in Hemophilia A (clinicaltrials.gov) - Jun 25, 2012
P4, N=0, Withdrawn, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Terminated --> Withdrawn N=18 --> 0
- Trial completion, Combination therapy: A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 24, 2012
P1, N=3, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=18 --> 0 Active, not recruiting --> Completed
- | melphalan / Generic mfg., amifostine / Generic mfg.
Enrollment closed: Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma (clinicaltrials.gov) - Jun 21, 2012
P3, N=130, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- long-acting sequence-modified recombinant factor VIIa (BAY 866150) / Bayer
New P2/3 trial: A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 (clinicaltrials.gov) - Jun 19, 2012
P2/3, N=10, Terminated, Sponsor: Bayer
- ||| BeneFix (nonacog alfa) / Pfizer
Trial completion, P4 data: Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B (clinicaltrials.gov) - Jun 19, 2012
P=N/A, N=183, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Mozobil (plerixafor) / Sanofi
Enrollment change: Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor (clinicaltrials.gov) - Jun 18, 2012
P4, N=9500, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed N=4800 --> 9500
- Review: Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=1200, Recruiting, Sponsor: University of Arkansas
- || lenalidomide / Generic mfg.
New P3 trial: UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 14, 2012
P3, N=300, Recruiting, Sponsor: University of Arkansas
- | Beqvez (fidanacogene elaparvovec-dzkt) / Pfizer
New P1/2 trial, Gene therapy, Viral vector: Hemophilia B Gene Therapy With AAV8 Vector (clinicaltrials.gov) - Jun 13, 2012
P1/2, N=15, Recruiting, Sponsor: Spark Therapeutics, LLC
- ||| gandotinib (LY 2784544) / Eli Lilly
Enrollment open: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - Jun 13, 2012
P1, N=100, Recruiting, Sponsor: Eli Lilly and Company
N=4800 --> 9500 Not yet recruiting --> Recruiting
- Trial termination: Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation (clinicaltrials.gov) - Jun 11, 2012
P1, N=4, Terminated, Sponsor: University of Medicine and Dentistry New Jersey
Not yet recruiting --> Recruiting Recruiting --> Terminated; Slow accrual
- Enrollment change: Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation (clinicaltrials.gov) - Jun 11, 2012
P1, N=4, Terminated, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Terminated; Slow accrual N=24 --> 4
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
Clinical: Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety. (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=50, Completed, Sponsor: Henri Mondor University Hospital
- Enrollment closed: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=30, Active, not recruiting, Sponsor: University of Medicine and Dentistry New Jersey
N=24 --> 4 Recruiting --> Active, not recruiting
- melphalan / Generic mfg., lenalidomide / Generic mfg.
New P2 trial: AMM-2011: Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Jun 10, 2012
P2, N=1, Terminated, Sponsor: University of Virginia
- Enrollment open: RCP-MM: Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=50, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- bortezomib / Generic mfg., dexamethasone / Generic mfg., dasatinib / Generic mfg.
Trial termination: Safety Study of Dasatinib With Bortezomib (Velcade (clinicaltrials.gov) - Jun 4, 2012
P1, N=16, Terminated, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Completed --> Terminated
- bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
Trial termination: S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P2, N=7, Terminated, Sponsor: Southwest Oncology Group
Completed --> Terminated Active, not recruiting --> Terminated; poor accrual
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P3, N=19, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Terminated; poor accrual Active, not recruiting --> Terminated; poor accrual
- SNS-032 / Viracta Therap
Enrollment change, Metastases: Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies (clinicaltrials.gov) - Jun 4, 2012
P1, N=21, Completed, Sponsor: Sunesis Pharmaceuticals
Active, not recruiting --> Terminated; poor accrual N=40 --> 21
- bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
Enrollment change: S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P2, N=7, Terminated, Sponsor: Southwest Oncology Group
N=40 --> 21 N=90 --> 7
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P3, N=19, Terminated, Sponsor: Southwest Oncology Group
N=90 --> 7 N=320 --> 19
- | SNS-032 / Viracta Therap
Trial completion, Metastases: Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies (clinicaltrials.gov) - Jun 4, 2012
P1, N=21, Completed, Sponsor: Sunesis Pharmaceuticals
N=320 --> 19 Active, not recruiting --> Completed